Pharma News

Views on biosimilars at Amgen and Actavis

Home/Pharma News | Posted 20/06/2014

Biotech giant Amgen and US generics maker Actavis entered into a collaboration for the development and commercialization of several cancer antibody biosimilars back in December 2011 [1]. Now the two companies have spoken to GaBI about their views on biosimilars and their biosimilar plans [2].

Top 10 most read GaBI Online articles in 2013

Home/Pharma News | Posted 07/02/2014

2013 was a busy year with lots of developments in the biosimilars arena, ranging from revision of regulatory guidelines to new biosimilar approvals. Biosimilars remain the hot topic of the year for GaBI Online during 2013 and in fact all 10 of the most read articles concern biosimilars.

Abbott expands generics business in Latin America

Home/Pharma News | Posted 06/06/2014

US-based pharma company Abbott Laboratories (Abbott) announced on 16 May 2014 that it was expanding its presence in Latin American and increasing its branded generics portfolio with the acquisition of CFR Pharmaceuticals (CFR).

Pamplona investment group buys majority share in Alvolgen

Home/Pharma News | Posted 16/05/2014

Specialist investment manager Pamplona Capital Management (Pamplona) announced on 2 April 2014 that it had acquired a majority stake in US generics company Alvogen, one of the fastest growing generics companies in the pharmaceutical industry.

Actavis to acquire generics from Akorn

Home/Pharma News | Posted 02/05/2014

US generics major Actavis announced on 17 April 2014 that it had made a deal with Akorn and Hi-Tech Pharmacal (Hi-Tech) to buy five of their products.

UK court invalidates Herceptin patents

Home/Pharma News | Posted 25/04/2014

A High Court in the UK has overturned two key patents on Roche’s breast cancer blockbuster Herceptin (trastuzumab).

Sun Pharma to acquire Ranbaxy creating 5th largest generics firm

Home/Pharma News | Posted 18/04/2014

India-based Sun Pharmaceutical (Sun Pharma) announced on 6 April 2014 that the company had agreed to acquire rival generics maker Ranbaxy Laboratories (Ranbaxy) in an all-stock deal worth US$3.2 billion.

Actavis buys Thai generics company

Home/Pharma News | Posted 11/04/2014

US generics major Actavis has acquired Silom Medical Company, a privately held generics firm focused on developing and marketing therapies in Thailand, for around US$100 million in cash.

US FTC hopes to collect US$1 billion from pay-for-delay settlement

Home/Pharma News | Posted 04/04/2014

The US Federal Trade Commission (FTC) is looking to collect more than US$1 billion from a settlement with pharmaceutical companies it has sued for their part in what the FTC terms ‘pay-for-delay’ deals.

Anticompetitive practices come under scrutiny in Australia

Home/Pharma News | Posted 28/03/2014

The Australian Competition and Consumer Commission (ACCC) has started proceedings in the Federal Court against Pfizer Australia (Pfizer) alleging that offers made by Pfizer to pharmacies before the expiry of the patents for its blockbuster cholesterol-lowering drug Liptor (atorvastatin) were anticompetitive.